Spruce Biosciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Revenue	10.09	0	0	0	0	0
Gross Profit	10.09	0	0	0	0	0
Selling, General & Admin	12.65	12.09	11.37	5.56	2.29	1.57
Research & Development	49.43	35.2	30.7	23.85	10.82	8.4
Operating Expenses	62.08	47.28	42.07	29.42	13.11	9.97
Operating Income	-51.99	-47.28	-42.07	-29.42	-13.11	-9.97
Interest Expense / Income	0.48	0.42	0.35	0.32	0.07	0
Other Expense / Income	-4.56	-1.52	-0.12	-0.2	-0.08	-0.11
Pretax Income	-47.92	-46.18	-42.29	-29.54	-13.09	-9.86
Net Income	-47.92	-46.18	-42.29	-29.54	-13.09	-9.86
Shares Outstanding (Basic)	39	24	23	6	1	5
Shares Outstanding (Diluted)	39	24	23	6	1	5
Shares Change	63.68%	0.71%	289.93%	683.77%	-84.44%	-
EPS (Basic)	-1.24	-1.96	-1.81	-4.93	-17.12	-2.01
EPS (Diluted)	-1.24	-1.96	-1.81	-4.93	-17.12	-2.01
Free Cash Flow	-33.28	-41.69	-35.97	-27.59	-12.62	-8.57
Free Cash Flow Per Share	-0.86	-1.77	-1.54	-4.61	-16.51	-1.74
Gross Margin	100.00%	-	-	-	-	-
Operating Margin	-515.34%	-	-	-	-	-
Profit Margin	-474.96%	-	-	-	-	-
Free Cash Flow Margin	-329.88%	-	-	-	-	-
EBITDA	-47.14	-45.33	-41.57	-29.11	-13.01	-9.86
EBITDA Margin	-467.20%	-	-	-	-	-
Depreciation & Amortization	0.3	0.43	0.38	0.1	0.01	0
EBIT	-47.44	-45.76	-41.95	-29.22	-13.02	-9.86
EBIT Margin	-470.18%	-	-	-	-	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).